Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Bone marrow transplant and pediatric multiple myeloma.

Davidow KA, Walter AW, Kolb EA.

Pediatr Blood Cancer. 2018 Nov 4:e27528. doi: 10.1002/pbc.27528. [Epub ahead of print]

PMID:
30393949
2.

A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group.

Isakoff MS, Goldsby R, Villaluna D, Krailo MD, Hingorani P, Collier A, Morris CD, Kolb EA, Doski JJ, Womer RB, Gorlick R, Janeway KA.

Pediatr Blood Cancer. 2018 Oct 30:e27524. doi: 10.1002/pbc.27524. [Epub ahead of print]

PMID:
30378256
3.

Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling.

Tarlock K, Zhong S, He Y, Ries R, Severson E, Bailey M, Morley S, Balasubramanian S, Erlich R, Lipson D, Otto GA, Vergillo JA, Kolb EA, Ross JS, Mughal T, Stephens PJ, Miller V, Meshinchi S, He J.

Oncotarget. 2018 May 29;9(41):26417-26430. doi: 10.18632/oncotarget.25443. eCollection 2018 May 29.

4.

Erratum: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions.

Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, Zhang J, Ma X, Liu Y, Liu Y, Auvil JMG, Davidsen TM, Gesuwan P, Hermida LC, Salhia B, Capone S, Ramsingh G, Zwaan CM, Noort S, Piccolo SR, Kolb EA, Gamis AS, Smith MA, Gerhard DS, Meshinchi S.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526b.

PMID:
29634680
5.

Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy.

Mills CC, Kolb EA, Sampson VB.

Cancer Res. 2018 Jan 15;78(2):320-325. doi: 10.1158/0008-5472.CAN-17-2782. Epub 2018 Jan 8. Review.

PMID:
29311160
6.

Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blinded, randomized controlled trial.

Dupuis LL, Kelly KM, Krischer JP, Langevin AM, Tamura RN, Xu P, Chen L, Kolb EA, Ullrich NJ, Sahler OJZ, Hendershot E, Stratton A, Sung L, McLean TW.

Cancer. 2018 Mar 15;124(6):1188-1196. doi: 10.1002/cncr.31198. Epub 2017 Dec 19.

PMID:
29266260
7.

The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions.

Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, Zhang J, Ma X, Liu Y, Liu Y, Auvil JMG, Davidsen TM, Gesuwan P, Hermida LC, Salhia B, Capone S, Ramsingh G, Zwaan CM, Noort S, Piccolo SR, Kolb EA, Gamis AS, Smith MA, Gerhard DS, Meshinchi S.

Nat Med. 2018 Jan;24(1):103-112. doi: 10.1038/nm.4439. Epub 2017 Dec 11. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

8.

Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer.

Mills CC, Kolb EA, Sampson VB.

Cancer Res. 2017 Dec 1;77(23):6489-6498. doi: 10.1158/0008-5472.CAN-17-2066. Epub 2017 Nov 2. Review.

PMID:
29097609
9.

Delivery of care consistent with the psychosocial standards in pediatric cancer: Current practices in the United States.

Scialla MA, Canter KS, Chen FF, Kolb EA, Sandler E, Wiener L, Kazak AE.

Pediatr Blood Cancer. 2018 Mar;65(3). doi: 10.1002/pbc.26869. Epub 2017 Oct 28.

PMID:
29080381
10.

MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia.

Lim EL, Trinh DL, Ries RE, Wang J, Gerbing RB, Ma Y, Topham J, Hughes M, Pleasance E, Mungall AJ, Moore R, Zhao Y, Aplenc R, Sung L, Kolb EA, Gamis A, Smith M, Gerhard DS, Alonzo TA, Meshinchi S, Marra MA.

J Clin Oncol. 2017 Dec 10;35(35):3964-3977. doi: 10.1200/JCO.2017.74.7451. Epub 2017 Oct 25.

11.

Down syndrome and AML: where do we go from here?

Tomizawa D, Kolb EA.

Blood. 2017 Jun 22;129(25):3274-3275. doi: 10.1182/blood-2017-04-780031. No abstract available.

12.

CRISPR/Cas9-Directed Reassignment of the GATA1 Initiation Codon in K562 Cells to Recapitulate AML in Down Syndrome.

Bloh KM, Bialk PA, Gopalakrishnapillai A, Kolb EA, Kmiec EB.

Mol Ther Nucleic Acids. 2017 Jun 16;7:288-298. doi: 10.1016/j.omtn.2017.04.009. Epub 2017 Apr 13.

13.

Implementing the psychosocial standards in pediatric cancer: Current staffing and services available.

Scialla MA, Canter KS, Chen FF, Kolb EA, Sandler E, Wiener L, Kazak AE.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26634. Epub 2017 May 19.

14.

Opportunities for expanding clinical trial enrollment for relapsed and refractory pediatric acute myeloid leukemia in the United States and Canada.

Alexander TB, Bhakta N, Kolb EA, Rubnitz JE.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26632. Epub 2017 May 16. No abstract available.

PMID:
28509405
15.

Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia.

Gopalakrishnapillai A, Kolb EA, McCahan SM, Barwe SP.

Leuk Res. 2017 Jul;58:91-97. doi: 10.1016/j.leukres.2017.05.004. Epub 2017 May 5.

16.

Cytotoxicity of Zardaverine in Embryonal Rhabdomyosarcoma from a Costello Syndrome Patient.

Cartledge DM, Robbins KM, Drake KM, Sternberg R, Stabley DL, Gripp KW, Kolb EA, Sol-Church K, Napper AD.

Front Oncol. 2017 Apr 3;7:42. doi: 10.3389/fonc.2017.00042. eCollection 2017.

17.

The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/βIII-Tubulin Axis.

Vetter NS, Kolb EA, Mills CC, Sampson VB.

Mol Cancer Res. 2017 Jul;15(7):953-964. doi: 10.1158/1541-7786.MCR-16-0372. Epub 2017 Mar 8.

18.

Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.

Tarlock K, Alonzo TA, Loken MR, Gerbing RB, Ries RE, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash SB, McKenney A, Kolb EA, Gamis AS, Meshinchi S.

Clin Cancer Res. 2017 Jul 15;23(14):3649-3656. doi: 10.1158/1078-0432.CCR-16-2353. Epub 2017 Jan 20.

19.

Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.

Sampson VB, Vetter NS, Zhang W, Patil PU, Mason RW, George E, Gorlick R, Kolb EA.

Oncotarget. 2016 Dec 27;7(52):86594-86607. doi: 10.18632/oncotarget.13358.

20.

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.

Kurmasheva RT, Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Kang M, Reynolds CP, Wu J, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26304. Epub 2016 Oct 27.

21.

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

Lock R, Carol H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Purmal A, Gudkov A, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26263. Epub 2016 Sep 21.

22.

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.

Murphy B, Yin H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Kurmasheva RT, Dvorchik I, Wu J, Billups CA, Boateng N, Smith MA, Lock RB, Houghton PJ.

Cancer Res. 2016 Oct 1;76(19):5798-5809. Epub 2016 Aug 5.

23.

Generation of Pediatric Leukemia Xenograft Models in NSG-B2m Mice: Comparison with NOD/SCID Mice.

Gopalakrishnapillai A, Kolb EA, Dhanan P, Bojja AS, Mason RW, Corao D, Barwe SP.

Front Oncol. 2016 Jun 27;6:162. doi: 10.3389/fonc.2016.00162. eCollection 2016.

24.

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

Kang MH, Reynolds CP, Kolb EA, Gorlick R, Carol H, Lock R, Keir ST, Maris JM, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2016 Oct;63(10):1744-52. doi: 10.1002/pbc.26064. Epub 2016 May 30.

25.

CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML.

Maxson JE, Ries RE, Wang YC, Gerbing RB, Kolb EA, Thompson SL, Guidry Auvil JM, Marra MA, Ma Y, Zong Z, Mungall AJ, Moore R, Long W, Gesuwan P, Davidsen TM, Hermida LC, Hughes SB, Farrar JE, Radich JP, Smith MA, Gerhard DS, Gamis AS, Alonzo TA, Meshinchi S.

Blood. 2016 Jun 16;127(24):3094-8. doi: 10.1182/blood-2016-04-709899. Epub 2016 May 3. No abstract available. Erratum in: Blood. 2017 Jan 5;129(1):134.

26.

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program.

Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Reynolds CP, Kang MH, Billups CA, Collins J, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2016 Mar;63(3):443-50. doi: 10.1002/pbc.25826. Epub 2015 Nov 24.

27.

Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies.

Kolb EA, Meshinchi S.

Hematology Am Soc Hematol Educ Program. 2015;2015:507-13. doi: 10.1182/asheducation-2015.1.507. Review.

PMID:
26637766
28.

Challenges in Converting Acute Myeloid Leukemia (AML) Genomics Into AML Clinical Trials.

Caywood EH, Kolb EA.

J Clin Oncol. 2015 Dec 20;33(36):4238-9. doi: 10.1200/JCO.2015.63.9252. Epub 2015 Nov 16. No abstract available.

PMID:
26573081
29.

Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.

Sampson VB, Vetter NS, Kamara DF, Collier AB, Gresh RC, Kolb EA.

PLoS One. 2015 Nov 16;10(11):e0142704. doi: 10.1371/journal.pone.0142704. eCollection 2015.

30.

Disruption of Annexin II /p11 Interaction Suppresses Leukemia Cell Binding, Homing and Engraftment, and Sensitizes the Leukemia Cells to Chemotherapy.

Gopalakrishnapillai A, Kolb EA, Dhanan P, Mason RW, Napper A, Barwe SP.

PLoS One. 2015 Oct 14;10(10):e0140564. doi: 10.1371/journal.pone.0140564. eCollection 2015.

31.

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.

Attiyeh EF, Maris JM, Lock R, Reynolds CP, Kang MH, Carol H, Gorlick R, Kolb EA, Keir ST, Wu J, Landesman Y, Shacham S, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2016 Feb;63(2):276-86. doi: 10.1002/pbc.25727. Epub 2015 Sep 23.

32.

MicroRNAs and Potential Targets in Osteosarcoma: Review.

Sampson VB, Yoo S, Kumar A, Vetter NS, Kolb EA.

Front Pediatr. 2015 Aug 24;3:69. doi: 10.3389/fped.2015.00069. eCollection 2015. Review.

33.

Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.

Roth M, Barris DM, Piperdi S, Kuo V, Everts S, Geller D, Houghton P, Kolb EA, Hawthorne T, Gill J, Gorlick R.

Pediatr Blood Cancer. 2016 Jan;63(1):32-8. doi: 10.1002/pbc.25688. Epub 2015 Aug 25.

PMID:
26305408
34.

Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.

Zwaan CM, Kolb EA, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R, De Bont ES, De Moerloose B, Dworzak M, Gibson BE, Hasle H, Leverger G, Locatelli F, Ragu C, Ribeiro RC, Rizzari C, Rubnitz JE, Smith OP, Sung L, Tomizawa D, van den Heuvel-Eibrink MM, Creutzig U, Kaspers GJ.

J Clin Oncol. 2015 Sep 20;33(27):2949-62. doi: 10.1200/JCO.2015.62.8289. Epub 2015 Aug 24. Review.

35.

Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.

Reynolds CP, Kang MH, Maris JM, Kolb EA, Gorlick R, Wu J, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2015 Nov;62(11):1897-905. doi: 10.1002/pbc.25611. Epub 2015 Jul 7.

36.

Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP).

Houghton PJ, Kurmasheva RT, Kolb EA, Gorlick R, Maris JM, Wu J, Tong Z, Arnold MA, Chatterjee M, Williams TM, Smith MA.

Pediatr Blood Cancer. 2015 Jul;62(7):1214-21. doi: 10.1002/pbc.25474. Epub 2015 Mar 23.

37.

A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.

Kolb EA, Sampson V, Stabley D, Walter A, Sol-Church K, Cripe T, Hingorani P, Ahern CH, Weigel BJ, Zwiebel J, Blaney SM.

Pediatr Blood Cancer. 2015 May;62(5):751-8. doi: 10.1002/pbc.25464. Epub 2015 Feb 27.

38.

Domestic pigs are susceptible to infection with influenza B viruses.

Ran Z, Shen H, Lang Y, Kolb EA, Turan N, Zhu L, Ma J, Bawa B, Liu Q, Liu H, Quast M, Sexton G, Krammer F, Hause BM, Christopher-Hennings J, Nelson EA, Richt J, Li F, Ma W.

J Virol. 2015 May;89(9):4818-26. doi: 10.1128/JVI.00059-15. Epub 2015 Feb 11.

39.

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, Lock RB, Keir ST, Maris JM, Billups CA, Lyalin D, Kurmasheva RT, Houghton PJ.

Clin Cancer Res. 2015 Feb 15;21(4):819-32. doi: 10.1158/1078-0432.CCR-14-2572. Epub 2014 Dec 10. Erratum in: Clin Cancer Res. 2017 Feb 15;23 (4):1118-1119.

40.

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program.

Kolb EA, Gorlick R, Keir ST, Maris JM, Kang MH, Reynolds CP, Lock RB, Carol H, Wu J, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2015 Jun;62(6):1106-9. doi: 10.1002/pbc.25329. Epub 2014 Nov 18.

41.

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA, Houghton PJ.

Pediatr Blood Cancer. 2015 Jan;62(1):91-8. doi: 10.1002/pbc.25201. Epub 2014 Sep 27.

42.

Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma.

Cao Y, Roth M, Piperdi S, Montoya K, Sowers R, Rao P, Geller D, Houghton P, Kolb EA, Gill J, Gorlick R.

PLoS One. 2014 Aug 29;9(8):e106249. doi: 10.1371/journal.pone.0106249. eCollection 2014.

43.

Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.

Houghton PJ, Kurmasheva RT, Lyalin D, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Smith MA.

Pediatr Blood Cancer. 2014 Nov;61(11):1972-9. doi: 10.1002/pbc.25175. Epub 2014 Aug 17.

44.

Oncolytic viruses for potential osteosarcoma therapy.

Hingorani P, Sampson V, Lettieri C, Kolb EA.

Adv Exp Med Biol. 2014;804:259-83. doi: 10.1007/978-3-319-04843-7_14. Review.

PMID:
24924179
45.

Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.

Kolb EA, Gorlick R, Billups CA, Hawthorne T, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2014 Oct;61(10):1816-21. doi: 10.1002/pbc.25099. Epub 2014 Jun 9.

46.

Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.

Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Wu J, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Lyalin D.

Pediatr Blood Cancer. 2014 Aug;61(8):1493-6. doi: 10.1002/pbc.25026. Epub 2014 Mar 24. Erratum in: Pediatr Blood Cancer. 2014 Sep;61(9):1716. Lyalin, Dmitry [added].

47.

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program.

Kang MH, Reynolds CP, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2014 Aug;61(8):1486-9. doi: 10.1002/pbc.24989. Epub 2014 Feb 20.

48.

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.

Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA, Lock R.

Pediatr Blood Cancer. 2014 Feb;61(2):245-52. doi: 10.1002/pbc.24724. Epub 2013 Sep 4.

49.

Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing Program.

Houghton PJ, Kurmasheva RT, Kolb EA, Wu J, Gorlick R, Maris JM, Smith MA.

Pediatr Blood Cancer. 2014 Feb;61(2):380-2. doi: 10.1002/pbc.24756. Epub 2013 Sep 9.

50.

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, Carol H, Lock R, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2014 Jan;61(1):158-64. doi: 10.1002/pbc.24616. Epub 2013 Aug 19.

Supplemental Content

Support Center